Pepscan Therapeutics establishes a Research Collaboration with Tibotec Pharmaceuticals
Pepscan Therapeutics announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target. Under the terms of the agreement, Pepscan will receive R&D funding and could receive payments on the achievement of research and clinical milestones, as well as royalties on sales of products resulting from the collaboration. Financial details of the agreement were not disclosed.
"Pepscan has recently realigned its R&D program to focus on the application of its proprietary CLIPS protein mimicry technology for the generation of novel therapeutic peptides and immunogens", said Wim Mol, CEO of Pepscan. "We are very pleased that Tibotec has decided to enter into a collaboration agreement with Pepscan that will utilize the CLIPS technology. We are convinced that our strong technology and expertise can yield improved peptides with superior activity and proteolytic stability, all this with a significantly shorter peptide." “We consider this agreement a further expression of our leadership position in the field of protein mimicry”, he added.
Other news from the department business & finance
